Idera Pharmaceutical Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (35)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Idera Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Idera Pharmaceutical. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in preclincal phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Idera Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Idera Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Idera Pharmaceutical. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in preclincal phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Idera Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Idera Pharmaceutical

  1.1 Business Overview

  1.2 Idera Pharmaceutical Cancer Pipeline Overview

 

2. Idera Pharmaceutical Cancer Drugs in Preclinical Phase

  2.1 Gene-Silencing Oligonucleotides - Idera Pharmaceuticals

  2.2 IMO 2055

  2.3 DNA- and RNA-Based Toll-Like Receptor Agonists - Idera Pharmaceuticals

  2.4 Toll-Like Receptor 9 Agonists - Idera/Merck KGaA

 

3. Idera Pharmaceutical Cancer Drugs in Phase-I/II

  3.1 IMO 2125

  3.2 IMO 8400 Companion Diagnostic - Abbott Laboratories

 

4. No Development Reported in Cancer Drugs in Clinical Pipeline

  4.1 Vaccines Containing Toll-Like Receptor Agonists - Idera/Merck

 

5. Discontinued in Cancer Drugs in Clinical Pipeline

  5.1 AEG 35156

  5.2 Veglin

  5.3 GEM 231

  5.4 Antisense Oligonucleotides VEGF - Idera Pharmaceuticals

  5.5 HYB 220

  5.6 Antisense Oligonucleotide MDM2 - Idera Pharmaceuticals

  5.7 HYB 190

 

6. Suspended in Cancer Drugs in Clinical Pipeline

  6.1 IMO 8400


Figure 1-1: Idera Pharmaceutical Cancer Pipeline by Phase (%)

Figure 1-2: Idera Pharmaceutical Cancer Pipeline by Phase (Number)

Figure 1 3: Idera Pharmaceutical Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1 4: Idera Pharmaceutical Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)